Compugen (CGEN) Net Income towards Common Stockholders (2009 - 2026)
Compugen (CGEN) reported Net Income towards Common Stockholders of $7.7 million for Q1 2026, up 7.59% on a YoY basis from $7.1 million in Q1 2025, and down 86.5% sequentially from $56.7 million in Q4 2025.
Compugen (CGEN) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
Compugen (CGEN) has 18 years of Net Income towards Common Stockholders data on file, last reported at $7.7 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 7.59% year-over-year to $7.7 million; the trailing twelve-month figure through Mar 2026 stood at $35.9 million (up 772.34% YoY), and the FY2025 full-year result was $35.3 million, up 348.35% from the prior year.
- Net Income towards Common Stockholders fell to $7.7 million in Q1 2026, from $56.7 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $56.7 million in Q4 2025 to a low of -$28.0 million in Q2 2023.
- A 5-year average of $1.4 million and a median of -$3.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders sank 198.03% in 2023 and jumped 1027.53% in 2025, its largest moves.
- Tracing CGEN's Net Income towards Common Stockholders over 5 years: stood at -$3.1 million in 2022, then jumped by 414.13% to $9.7 million in 2023, then sank by 162.98% to -$6.1 million in 2024, then jumped by 1027.53% to $56.7 million in 2025, then plunged by 86.5% to $7.7 million in 2026.
- Business Quant data shows CGEN's Net Income towards Common Stockholders at $7.7 million in Q1 2026, $56.7 million in Q4 2025, and -$6.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.47 Bn | 466.67 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.76 Bn | 114.52 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.15 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - | -0.68 |
| 8 | Argenx Se | 55.77 Bn | 50.59 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.45 Bn | 37.45 Bn | - | -453.82 Mn |
| 10 | Compugen | 224.57 Mn | 132.82 Mn | 352,000.00 | 7.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.66 Mn |
| Dec 31, 2025 | 56.74 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | -21.61 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | -6.12 Mn |
| Sep 30, 2024 | 10.28 Mn |
| Jun 30, 2024 | -16.62 Mn |
| Mar 31, 2024 | 7.26 Mn |
| Dec 31, 2023 | 9.71 Mn |
| Sep 30, 2023 | -9.85 Mn |
| Jun 30, 2023 | -28.00 Mn |
| Mar 31, 2023 | 9.31 Mn |
| Dec 31, 2022 | -3.09 Mn |
| Sep 30, 2022 | -11.75 Mn |
| Jun 30, 2022 | 28.56 Mn |
| Mar 31, 2022 | -9.71 Mn |
| Dec 31, 2021 | -8.65 Mn |
| Sep 30, 2021 | -8.18 Mn |
| Jun 30, 2021 | -9.50 Mn |